Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® (ixekizumab): What was the incidence of Candida infections in clinical trials?

In clinical trials, oral candidiasis occurred more frequently in the ixekizumab group than in the placebo group.

Ixekizumab Label Information Related to Infections

Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.1

Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.1

In controlled studies, for up to 24 weeks, oral candidiasis was uncommonly reported (≥ 1/1.000 to < 1/100).1

Psoriasis

Incidence of Candida Infections from UNCOVER Phase 3 Clinical Trials

In the UNCOVER clinical trials, Candida infections occurred in 1.4% of patients who received ixekizumab 80 mg Q2W and in 0.6% of patients who received ixekizumab 80 mg Q4W through week 12.2,3

Oral candidiasis occurred more frequently in the ixekizumab group than in the placebo group. In the first 12 weeks of treatment, dose-dependent oral candidiasis was observed with ixekizumab. Across the trials, oral candidiasis was reported in

  • 0.8% of patients dosed with ixekizumab Q2W (p<.05 vs Q4W)

  • 0.2% of patients dosed with ixekizumab Q4W

  • 0.1% of patients dosed with etanercept, and

  • 0.0% of patients dosed with placebo.4

Overall, Candida infections were noninvasive and did not lead to discontinuation.4 Most cases were mild-to-moderate in severity, and resolved with standard oral or topical antifungal treatments.2,5 One patient who received ixekizumab 80 mg Q2W experienced a moderate skin Candida infection of the axilla and groin, which was treated with topical clotrimazole twice daily for 1 month, followed by a topical combination product containing isoconazole and corticosteroid for approximately 2 weeks. The patient continued treatment with ixekizumab.2

The EAIR of Candida infections during weeks 0 through 60 was similar to the rate during weeks 0 to 12.3

In patients exposed to ixekizumab across the 3 pivotal UNCOVER trials (N=3736), the EAIR for all Candida infections with ixekizumab was

  • 3.7 per 100 PY for weeks 0 to 60 (n=128), and

  • 6.0 per 100 PY for weeks 0 to 12 (n=16) (ixekizumab 80 mg Q2W only).3

Through week 60 of these trials, 2 patients had esophageal candidiasis confirmed by gastroscopy (both moderate-severity) and neither patient discontinued from the study due to their infection.3

All Ixekizumab Psoriasis Exposures

In a larger integrated analysis of data across 15 adult and 1 pediatric plaque psoriasis clinical trials as of March 2020 (N=6645; 17,902 PYs of exposure), the IR of Candida infections was 1.9 per 100 PYs.6 Fourteen cases of esophageal candidiasis were reported, and 2 of which were categorized as an SAE. No cases of deep organ or blood stream candidiasis were reported in the safety analysis.7

Psoriatic Arthritis

Incidence of Candida Infections Through Week 24 From SPIRIT-P1 and SPIRIT-P2 Phase 3 Clinical Trials

In the SPIRIT-P1 and SPIRIT-P2 PsA trials, Candida infections occurred in 3.6% of patients who received ixekizumab 80 mg Q2W and in 1.7% of patients who received ixekizumab 80 mg Q4W through week 24.8

Candida infection occurred more frequently in patients who received ixekizumab than in patients who received placebo.8 Most Candida infections during the first 24 weeks of SPIRIT-P1 and SPIRIT-P2 were mild or moderate in severity. No patients discontinued from the studies due to Candida infections.7

One TEAE of esophageal candidiasis was reported as an SAE.7,9

All Ixekizumab Psoriatic Arthritis Exposures

In a larger integrated analysis of data across 4 PsA trials as of March 2020 (N=1401; 2247.7 PYs of exposure), the IR of Candida infections was 2.0 per 100 PYs. Two cases of esophageal candidiasis were reported, both of which were categorized as an SAE. No cases of deep organ or blood stream candidiasis were reported in the safety analysis.7

Axial Spondylarthritis

Incidence of Candida Infections Through week 16 of AS/r-axSpA Trials

In the 16-week, double-blind treatment period of COAST-V, no cases of Candida infections were reported in ixekizumab or placebo groups. One case of skin Candida infection was reported in the adalimumab active reference arm.10

In the 16-week, double-blind treatment period of COAST-W, 2 Candida infections were reported in the ixekizumab Q2W study arm (1 esophageal and 1 genital candidiasis). No infections were reported in the placebo group.11 

52-week Double-Blind Treatment Period of Nonradiographic Axial Spondyloarthritis Trial

No cases of oral candidiasis were reported in either ixekizumab treatment group in COAST-X through week 52. One case of oral candidiasis was reported in a patient in the placebo group.12

All Ixekizumab Axial Spondyloarthritis Exposures

In an integrated safety analysis across 4 axSpA trials (including AS/r-axSpA and nr-axSpA) (N=932; 1849.0 PYs of exposure to ixekizumab) with data as of March 2020, the IR of Candida infection was 1.4 per 100 PYs.13 Four cases of esophageal candidiasis were reported and none of which were reported as an SAE. No cases of deep organ or blood stream candidiasis were reported in the safety analysis.7

Please note that some dosing schedules mentioned in this response are not consistent with the approved dosing schedule. Please refer to the Taltz Summary of Product Characteristics for approved dosing. 1

References

1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551. http://dx.doi.org/10.1016/S0140-6736(15)60125-8

3. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

4. Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432-440.e17. http://www.sciencedirect.com/science/article/pii/S0190962216308684

5. Papp K, Winthrop KL, Braun D, et al. Safety and tolerability of ixekizumab: analysis of infections in 7 clinical studies of moderate-to-severe plaque psoriasis. Poster presented at: 24th European Academy of Dermatology and Venereology Congress; October 7-11, 2015; Copenhagen, Denmark.

6. Griffiths CEM, Reich K, Gooderham M, et al. Long-term safety of ixekizumab in patients with moderate-to-severe psoriasis up to 5 years: pooled data from 16 clinical trials. Poster presented at: 29th Annual Meeting of the European Academy of Dermatology and Venereology (EADVirtual); October 29-31, 2020.

7. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

8. Combe B, Rahman P, Kameda H, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: An integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14. http://dx.doi.org/10.1186/s13075-020-2099-0

9. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. http://dx.doi.org/10.1136/annrheumdis-2016-209709

10. van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441-2451. http://dx.doi.org/10.1016/s0140-6736(18)31946-9

11. Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599-611. http://dx.doi.org/10.1002/art.40753

12. Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53-64. http://dx.doi.org/10.1016/S0140-6736(19)32971-X

13. Schwartzman S, Sandoval D, Kronbergs A, et al. Long-term safety profile of ixekizumab treatment on patients with axial spondyloarthritis. Abstract presented at: American College of Rheumatology/ARP 2020 Annual Scientific Meeting (Virtual); November 5-9, 2020.

Glossary

AS/r-axSpA = ankylosing spondylitis/radiographic axial spondyloarthritis

axSpA = axial spondyloarthritis

EAIR = exposure adjusted incidence rate

IR = incidence rate

nr-axSpA = nonradiographic axial spondyloarthritis

PsA = psoriatic arthritis

PY = patient-years

Q2W = every 2 weeks

Q4W = every 4 weeks

SAE = serious adverse event

TEAE = treatment-emergent adverse event

Date of Last Review: November 09, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question